Combination chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone in the treatment of malignant lymphomas.
D000284:Administration, Oral; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007275:Injections, Intravenous; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use*
D011344:Procarbazine; D014747:Vinblastine; D003520:Cyclophosphamide; D011241:Prednisone